<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552667</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MOLZ-302</org_study_id>
    <nct_id>NCT02552667</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HCP1102 Capsule</brief_title>
  <official_title>Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled,&#xD;
      multicenter phase 3 clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Mean Daytime Nasal Symptom Score</measure>
    <time_frame>base line, 3-4week(2weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Daytime Nasal Symptom Score</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Runny nose (Mean Daytime Nasal Symptom Score)</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Nighttime Nasal Symptom Score</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Composite Symptom Score</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sneezing (Mean Daytime Nasal Symptom Score)</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pruritus (Mean Daytime Nasal Symptom Score)</measure>
    <time_frame>base line, 1-2week(2weeks), 3-4week(2weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Asthma With Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>HCP1102+HGP0711Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1102Placebo+HGP0711Placebo(1week) -&gt; HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP1102Placebo+HGP0711</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCP1102Placebo+HGP0711Placebo(1week) -&gt; HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1102+HGP0711Placebo</intervention_name>
    <description>Coadministration of HCP1102 with HGP0711 Placebo for 4-week</description>
    <arm_group_label>HCP1102+HGP0711Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1102Placebo+HGP0711</intervention_name>
    <description>Coadministration of HCP1102 Placebo with HGP0711 for 4-week</description>
    <arm_group_label>HCP1102Placebo+HGP0711</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Ageâ‰¥15&#xD;
&#xD;
          -  Mild or moderate asthma patients with allergic rhinitis&#xD;
&#xD;
          -  Patient who meet all criteria of rhinitis&#xD;
&#xD;
          -  Patients understood the contents and purpose of this trial and signed informed consent&#xD;
             form&#xD;
&#xD;
          -  Patients who are capable and willing to write subject diary&#xD;
&#xD;
          -  Patients who agree with maintain same environment during clinical trials&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Nonallergic rhinitis&#xD;
&#xD;
          -  Severe asthma&#xD;
&#xD;
          -  Other pulmonary disease (pulmonary tuberculosis, COPD) except Asthma&#xD;
&#xD;
          -  Medical history of hypertrophic cardiomyopathy, cancer, renal disease, Liver disease,&#xD;
             cardiovascular disease, respiratory disease, endocrine disorder, CNS disorder that&#xD;
             effect safety&#xD;
&#xD;
          -  Medical history of gastrointestinal surgery or gastrointestinal disorders that effect&#xD;
             drug absorption&#xD;
&#xD;
          -  Alcohol abuse or Drug abuse&#xD;
&#xD;
          -  Genetic factor of galactose intolerance or Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          -  pregnant or breast-feeding women or men/women of childbearing age that they don't use&#xD;
             contraceptives&#xD;
&#xD;
          -  Patient who administered other investigational products within 30 days&#xD;
&#xD;
          -  Current smoker Judged to be inappropriate for the study by the investigator after&#xD;
             reviewing other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon-Sik Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soon Chun Hyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <state>Gyunggi -do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

